Trials / Completed
CompletedNCT02524678
Phase 1 Study(Additional) of URC102 in Healthy Subjects
A Phase I, Placebo-controlled, Randomized, Double Blind, Dose-escalation Study to Assess the Safety and Pharmacokinetic and Pharmacodynamic Characteristics of Repeated-dose URC102 in Healthy Korean Adult Males
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- JW Pharmaceutical · Industry
- Sex
- Male
- Age
- 20 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety, tolerability, PK and PD of URC102 in healthy subjects.
Detailed description
Tolerability, safety, and pharmacokinetics (PK) of URC102 will be assessed after 7-day repeated oral dose in healthy adult Korean males. In addition, pharmacodynamic (PD) response of blood and urinary uric acid levels will be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | |
| DRUG | URC102 |
Timeline
- Start date
- 2015-08-05
- Primary completion
- 2015-10-07
- Completion
- 2016-03-28
- First posted
- 2015-08-17
- Last updated
- 2020-02-13
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02524678. Inclusion in this directory is not an endorsement.